daily, SFC 50/250 μg twice daily, or Tio 18 μg once daily plus SFC 50/250 μg twice daily. Pulmonary function, CT, and assessment of health-related quality of life were carried out at screening and at the end of treatment. The right upper lobe apical segmental bronchus (RB1) was chosen for the analysis. The luminal area (Ai), total area of the airway (Ao), wall area (WA = Ao -Ai), percentage wall area (WA% = WA/Ao × 100), and absolute wall thickness were automatically computed. The addition of Tio to SFC significantly increased the Ai and decreased the airway wall thickness. Furthermore, FEV 1 significantly increased in the Tio-plus-SFC group compared with the other groups and this effect was correlated with the changes in Ai and WA. Anatomical and functional changes were associated with greater improvements in SGRQ subscores of symptoms and activity in the Tioplus-SFC group compared with the Tio, SM, and SFC groups.
Chronic obstructive pulmonary disease (COPD) is a common respiratory disease that represents the third leading cause of death and disease burden worldwide. By definition, it is treatable, but the effectiveness of the current treatment is unsatisfactory since it results in little changes in the natural history of the disease [1] . Drugs for stable COPD reduce the symptoms, frequency, and severity of exacerbations and improve the quality of life and exercise tolerance, but none of them consistently attenuate the progressive decline in FEV 1 . The positive effects on FEV 1 decline obtained with an inhaled corticosteroid/ long-acting β 2 -agonist (ICS/LABA) combination or tiotropium (Tio) have been demonstrated only in post hoc analysis or subanalysis of the TORCH and UPLIFT studies [2, 3] . Furthermore, few data have been reported on the ability of the current drugs to modify biomarkers of remodeling in COPD patients [4, 5] . Triple combination therapy with anticholinergics, ICS, and LABA improved pulmonary function and symptoms in COPD patients [6] , but the mechanism behind the increased efficacy has not been studied.
In the current issue of Respiration, Hoshino and Ohtawa [7] report the effects of Tio plus salmeterol and fluticasone propionate (SFC) on airway dimensions as assessed by chest tomography (CT) scan in COPD patients. A total of 60 COPD patients were treated for 16 weeks with Tio 18 μg once daily, salmeterol (SM) 50 μg twice
The explanation for the findings remains undetermined. One possibility is geometrical in nature due to more bronchodilation under triple treatment, since the second CT was performed while the subjects were under the effect of bronchodilators. This explanation is in line with the correlation between airway structural changes and FEV 1 . Since the total airway area did not change, reduced folding of the mucosa during bronchodilation might be admitted for increased luminal area and decreased thickness.
A second more interesting hypothesis is an effect on airway remodeling. Despite several studies showing an improvement in markers of airway inflammation in COPD patients treated with ICS or ICS/LABA combinations [4, 5, 8] , limited observations have been reported on the effects on airway remodeling [9, 10] . The hypothesis that triple therapy may modify airway remodeling in COPD is particularly interesting and requires confirmation in a large long-term clinical trial. If a reduction in the remodeling process is obtainable with triple therapy, this might change the current recommendations of treating patients with increasing levels of pharmacologic therapy only in relation to the severity of symptoms and airway limitation [1] . If triple therapy has the possibility to modify FEV 1 decline, which is greater in mild-moderate than in severe COPD patients, then it should be initiated from the beginning of the disease and not at the end stage of COPD. Obviously, this should be balanced by the higher risk of long-term side effects and the higher cost of the treatment.
The paper from Hoshino and Ohtawa [7] has, however, some limits. Firstly, a treatment arm with Tio and SM association without ICS was not considered, leaving open the question of whether ICS are needed to see such changes. Secondly, the study has a low number of patients in each arm and did not include a placebo one. Thirdly, the bronchodilating effect of treatment is a confounder in the interpretation of the results. If changes in airway wall thickness had been detected after triple treatment in CT scans performed after withdrawal of bronchodilators for an appropriate interval, the hypothesis of an airway remodeling would be stronger. Finally, only one segmental bronchus (RB1) was assessed and, even though Aysola et al. [11] suggested that airway measurements of RB1 correlated with other proximal airways, this method does not provide information on the peripheral lung where relevant pathologic processes take place [12] .
In summary, the study gives some support to the potential usefulness of triple combination therapy in the management of COPD. However, the relationship between clinical, physiological, and inflammatory features of COPD and remodeling is still poorly understood.
